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Abstract The hypertrophy of the arterial media exhibited by 
spontaneously hypertensive rats is related to the hyperprolifera- 
tion of their smooth muscle cells in culture. Using two methods to 
assay nitric oxide synthase activity, we showed that this 
abnormal proliferation results from a decreased activity of the 
inducible NOS II and less modulation of this enzymatic activity 
by these cells compared to control Wistar Kyoto cells. 
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1. Introduction 
Spontaneously hypertensive rats (SHR) have been proposed 
as a model of human essential hypertension, with hypertrophy 
of the vascular media [1] and dysregulation of immune func- 
tion [2]. In culture, vascular smooth muscle cells (VSMC) 
from SHR proliferate more than those from normotensive 
Wistar Kyoto rats (WKY) [3,4], as demonstrated by increases 
of both leucine incorporation into cell proteins [5] and thymi- 
dine uptake during DNA synthesis [4]. 
Nitric oxide (NO), which is the endothelium-derived relax- 
ing factor involved in the regulation of VSMC contraction 
[6,7], has been shown to inhibit thymidine incorporation 
and thus DNA synthesis [8,9]. All these properties suggest 
the possible involvement of NO in cell proliferation. 
To examine this possibility, NO synthase (NOS) activities in 
cultured VSMC from WKY and SHR was evaluated. The 
hyperproliferation of the latter may be the result of decreased 
activity of the inducible NOS produced by these cells com- 
pared to that from WKY cells. 
2. Materials and methods 
2.1. Cell culture 
VSMC were extracted from the thoracic aorta of WKY and SHR 
rats and cultured as described by Inoue et al. [10]. 
All assays were performed in flat-bottomed 96-well (0.33 cm 2 each) 
culture plates. 104 cells per well were plated in 100 ~tl of DMEM 
(Gibco, Cergy-Pontoise, France) containing 100 U/ml of penicillin, 
100 U/ml of streptomycin, and 10% heat-inactivated fetal calf serum 
(FCS). After 24 h, the medium was replaced with serum-free DMEM 
and cells were cultured for 48 h so as to obtain homogeneous Go 
phase cells. The cells were then stimulated for various times with 
5% FCS, with or without the following compounds: (i) lipopolysac- 
charide (LPS) or interleukin-1 beta (I1-113), as inducers of NOS II; (ii) 
N G-nitro-L-arginine methyl ester (L-NAME), as an inhibitor of NOS. 
Cells were counted according to the method of Kueng et al. [11]: 
briefly, cells were fixed with 1% glutaraldehyde and stained with 
0.1% crystal violet in MES buffer; the intracellular crystal violet 
was extracted with 100 t.tl of 10% acetic acid and the optical density 
(OD) was read at 590 nm, using an MR 7000 microplate reader 
(Dynatech, Elancourt, France). 
2.2. Nitrite assay 
100 ~tl of Griess reagent, constituted of 1 vol. of naphthylethylene 
diamine solution (0.2% in bidistilled water) and 1 vol. of sulfanyl- 
amide solution (2% in 5% phosphoric acid), were added to each 
well containing plated VSMC in 100 I.tl of culture medium. After 1 
h at 4°C, the OD was read at 550 nm in the microplate reader. 
2.3. Citrulline measurement 
To start stimulation, 3.7 kBq of L-[U-14C]arginine (12 GBq/mmol, 
Amersham-France, Les Ulis, France) were added to each well, con- 
taining 100 ktl of medium and cultured VSMC. At each selected time, 
10 ktl of the cell medium were applied as a linear spot on precoated 
silica gel HPTLC 60 plates (Merck, Darmstadt, Germany). The dif- 
ferent radiolabeled L-arginine metabolites were separated using the 
solvent system described by Ivengar et al. [12]. The plates were then 
scanned with an automatic TLC linear LB 283 analyzer (Berthold, 
Evry, France). 
3. Results and discussion 
Fig. 1A shows the time course of VSMC proliferation over 
48 h. No significant differences between the numbers of SHR 
and WKY cells could be observed until 24 h. After this time, 
SHR VSMC increased markedly in number while the WKY 
cell number remained stable. On the other hand, Fig. 1B 
shows that WKY cells secreted much more citrulline into 
the culture medium after 24 h while citrulline release by 
SHR was unchanged. Uehara et al. [5] previously observed 
similar kinetics of leucine incorporation and thus protein 
synthesis. NOS generates both citrulline and NO which is 
an inhibitor of DNA synthesis. Thus, the time-dependent ac- 
cumulation of citrulline in the cell medium can be used as a 
characteristic marker of NOS activity, as already demon- 
strated [12]. After its generation, NO is rapidly transformed 
into nitrites [12] and measurement of the nitrite level revealed 
(Fig. 1C) parallel accumulation of citrulline and nitrites, both 
being higher for WKY than SHR VSMC. Thus, NOS product 
secretion by SHR VSMC was lower than that of WKY cells 
and is in agreement with the higher proliferation level of SHR 
VSMC in the presence of FCS. 
Fig. 2 gives the mean values of NOS activity for WKY and 
SHR VSMC measured on 3 separate cell preparations at 24, 
30 or 48 h. For each individual experiment in the presence of 
5°/,, FCS alone, the ratio of SHR/WKY NOS products was 
between 31 and 49%. These results confirm the lower NOS 
activity of SHR VSMC in culture. Moreover, the addition of 
LPS, an inducer of NOS activity, characteristically enhanced 
this activity in WKY cells while that in SHR VSMC was 
unaffected. Similarly, WKY VSMC exhibited increased citrul- 
line production in the presence of I1-113 and decreased citrul- 
line secretion in the presence of L-NAME, while SHR citrul- 
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line values were unchanged by any modulator, thereby sug- 
gesting a weaker induction of NOS II activity in SHR than 
WKY VSMC. Nitrite level were modulated in the same man- 
ner in WKY cells, but this time SHR VSMC responses par- 
alleled them, albeit to a lesser extent. In this study, the num- 
bers of cells counted after the action of LPS, I1-1~ or L- 
NAME were not significantly different when compared to 
the number of control cells, i.e. with only 5% FCS. 
This smaller increase in NO secretion has already been re- 
ported for SHR endothelial cells after stimulation by brady- 
kinin for constitutive NOS III, and for VSMC after induction 
by 11-113 in the absence of serum for NOS II [13] which is only 
present in VSMC [14]. On the other hand, Nava et al. [15] 
observed a lower specific activity of the inducible NOS II in 
SHR cardiac cells, compared to WKY cells. 
The markedly lower nitrite and citrulline levels secreted into 
the cell medium by SHR VSMC compared to the WKY 
VSMC observed in this study occurred essentially during the 
M phase of the cell cycle. This decrease could partially explain 
the hyperproliferation f SHR cells. Three hypotheses can be 
proposed to explain this observation: (1) lower expression of 
the NOS II gene by the SHR cells, resulting in the action of 
other compounds, as was previously shown for I1-113 [16]; (2) 
decreased transfer of NOS II from the cytosolic storage vesi- 
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Fig. 1. Time course of cell number (A), citrulline (B) and nitrite (C) 
accumulation i the cell culture medium of VSMC from WKY (I) 
and SHR ([]) after stimulation with 5% FCS. Each point represents 
the mean + S.D. of 3 experiments. 
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Fig. 2. Citrulline and nitrite accumulation i  the culture medium of 
WKY (dark bars) and SHR (light bars) VSMC in the presence of 
5% FCS alone (control) and in combination with LPS (10 and 20 
~g/ml), I1-113 (20 ng/ml) or L-NAME (100 ~tM). Values are 
means + S.D. (n = 4). 
cles to the plasma membrane where it becomes activated [17]; 
and (3) dysregulation of the transmembrane s cretion of NOS 
products in SHR cells. The higher level of cell membrane 
peroxidation found for the SHR VSMC according to the 
method described in [18] is under investigation and could 
support the two latter hypotheses. 
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